Novo Nordisk S.p.A., legal representative in Italy of Novo Nordisk A/S, has notified AIFA and EMA that the permanent marketing cessation of the medicine Victoza® (liraglutide) is planned in all EU/EEA countries.

This discontinuation could lead to intermittent short-term shortages in some countries. The marketing cessation of Victoza® in Italy will take effect on 30 June 2026.

Healthcare professionals are advised not to prescribe Victoza® to new patients and to safely transfer patients already on treatment to an alternative therapy from among those available.